NCT05816746 2023-05-09
Decitabine and Anti-PD-1 in R/R DLBCL
Chinese PLA General Hospital
Phase 2 Unknown
Clinical Trials
12 trialsNCT05320640 2022-04-11
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT05137886 2021-12-17
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04025593 2020-11-19
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04233294 2020-08-14
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT04510610 2020-08-12
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2/3 Unknown
NCT04279379 2020-05-07
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 2 Unknown
NCT02951728 2020-03-11
DR-CHOP
Ruijin Hospital
Phase 1/2 Unknown
NCT03250962 2019-04-01
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT03558412 2018-09-14
A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
Zhengzhou University
Phase 4 Unknown
NCT03579082 2018-09-14
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
Zhengzhou University
Phase 4 Unknown
NCT03553537 2018-06-12
Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Southwest Hospital, China
Phase 3 Unknown